Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine in Outpatient Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with diagnosis of COVID-19 via an approved or authorized molecular test~* Presence of symptoms compatible with COVID-19 at the time of screening~* Time between onset of symptoms and first dose of hydroxychloroquine or placebo is 96 hours or less~* Female participants must use an acceptable birth control method, as specified by each site and country~Exclusion criteria:~* COVID-19 disease requiring the use of supplemental oxygen~* Electrocardiogram (ECG) tracing with QTc interval \> 450 ms for men, \> 470 ms for women (Fridericia algorithm recommended)~* Bradycardia (\< 50 beats/min)~* History of cardiac disease (eg. congestive heart failure, myocardial infarction)~* History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Women who are pregnant or breastfeeding~* Concurrent antimicrobial therapy~* Known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds~* Hydroxychloroquine use within 2 months before enrollment~* History of severe skin reactions such as Sevens-Johnson syndrome and toxic epidermal necrolysis~* History of retinopathy~* History of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of sudden cardiac death~* History of severe renal disease (treatment with dialysis or phosphate binders) or hepatic impairment~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).